Alzheimer and Longevity Research Turn to Nanomedicine and AI

Nanomedicine is being explored as a way to deliver therapeutic agents across the blood‑brain barrier for Alzheimer disease. By coating active compounds in nanoparticles such as liposomes, dendrimers or exosomes, researchers hope to bypass the barrier that blocks most drugs, and nanobiosensors are under development for early detection of amyloid‑beta and tau proteins in blood before cognitive symptoms appear. Past failures of amyloid‑targeting antibodies have underscored the need for new delivery approaches.

In parallel, scientists are using artificial intelligence and cellular reprogramming techniques to address age‑related decline. AI models analyze massive biological data sets to identify promising targets, while Yamanaka factors are being tested to reset cellular ageing, with early clinical trials aimed at conditions such as glaucoma. The broader goal is to delay the onset of diseases like Alzheimer, cardiovascular and metabolic disorders, offering potential economic benefits for ageing societies.